Wave Life Sciences Initiates Phase 2a Trial for WVE-007 in Obesity
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA product, in combination with tirzepatide for adults with obesity. The company plans to use the trial to assess WVE-007 in monotherapy, combination therapy, and as a post-incretin maintenance therapy to prevent weight regain.
From finanznachrichten.de
Why it matters
Preclinical and clinical information suggests WVE-007 may enhance fat loss while preserving muscle mass compared to incretins used alone. The company is also evaluating WVE-007 for MASH indications.
From finanznachrichten.de
Who's involved
- Wave Life SciencesBiotechnology company conducting the clinical trial for WVE-007
Keep exploring
The entities involved
-
Wave Life Sciences
biotechnology company
Nothing else this week.
-
mash
fast genome and metagenome distance estimation using MinHash
Nothing else this week.